Abstract: Use of eliprodil and its enantiomers for the preparation of medicines useful for the treatment of peripheral nouropathies and chronic neurodegenerative diseases of the central nervous system.

Abstract: An aqueous cosmetic or dermo-pharmaceutical composition contains, in suspension in the continuous phase, hydrated spheroids of a hydrophilic lipidic substance. The hydrated spheroids have an average particle diameter ranging from 50 to 10,000 .mu.m. A process for the preparation of this composition is described.

Abstract: Use of 2-amino-6-(trifluoromethoxy)benzothiazole, or a salt of this compound with a pharmaceutically acceptable acid, for obtaining a medicament intended for the treatment of motor neuron diseases, in particular amyotrophic lateral sclerosis, and especially amyotrophic lateral sclerosis with early bulbar involvement or the bulbar form of the disease.

Abstract: New uses of certain substituted pyrido[1,2-a]pyrimidin-4-one anti-allergy drugs are made possible by the provision of clear, stable aqueous solutions of same. The aqueous solutions contain novel combinations of drugs and stabilizers.

Abstract: Galanthamine and the pharmaceutically suitable acid addition salts thereof can be used for the treatment of alcoholism; these compounds are released from adequate pharmaceutic formulations which are administered, e.g., orally, transdermally, or otherwise parenterally, in a continuous and controlled manner.

Abstract: The use of lidocaine or other Class I cardiac antiarrhythmic compound in the management of preterm labor and the stoppage of labor preparatory to cesarian delivery, is disclosed. The electrophysiological effects of lidocaine on the sodium, calcium and potassium channels of freshly dissociated myocytes from late-pregnant rat uteri with the tight-seal patch-clamp method are presented. Dose-response relations on the sodium and calcium currents, and effects on the availability relation for sodium current are also presented. Also disclosed are the effects of chronic administration of lidocaine on the duration of pregnancy.

Abstract: Pharmaceutical compositions for the improvement of dysuria comprising a pharmaceutical carrier and a therapeutically effective amount of a xanthine derivative represented by the general formula I ##STR1## wherein R.sub.1 denotes a group of the formula R.sub.4 -CO- or R.sub.5 R.sub.6 (OH)C- or a carboxyl group, wherein R.sub.4 and R.sub.5 independently denote an alkyl group having 1-3 carbon atoms, and R.sub.6 denotes a hydrogen atom or an alkyl group having 1-3 carbon atoms, R.sub.2 denotes a hydrogen atom, an alkyl group having 1-5 carbon atoms or an alkyloxy group having 1-5 carbon atoms, R.sub.3 denotes an alkyl group having 1-3 carbon atoms and n denotes 1-6 or a pharmaceutically acceptable acid addition salt thereof.They are active in prolonging urination intervals and increasing urination threshold pressure with almost no influence upon constrictive force of the bladder. Thus, they are effective in treatment and prevention of dysuria such as pollakiuria and incontinence of urine.

Abstract: A pharmaceutical formulation comprising a substantially clear aqueous solution having a viscosity of less than 10 mPa.s containing 3.5 to 5% w/v of 1,3-bis(2-carboxychromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable salt thereof, as active ingredient and glycerol, the concentration of ions of metals of groups IIA, IB, IIB and IVB of the periodic table or of transition metals being less than 20 ppm.

Abstract: The rate and character of mammalian hair growth is altered by the topical application to the skin of a composition containing an organic inhibitor of the enzyme L-asparagine synthetase.

Abstract: Repetitive administrations of cocaine over a period of days causes the animal body to become more sensitive to the drug. A dose of cocaine that was not toxic to a novice user may be toxic or even lethal to an habituated user. These toxic effects include craving, seizures, brain ischemia and death. The mechanism of action of these toxic effects appears to be through the glutamatergic neurotransmitter system as evidenced by blocking with antagonists for N-methyl-D-aspartate receptors. However, these antagonists have undersirable side effects. Applicant demonstrates that the toxic effects of repetitive cocaine administrations can be reversed by the administration of inhibitors of the enzyme nitric oxide synthase which is also involved in the neurotransmitter system. The drugs which inhibit the enzyme nitric oxide synthase include N-nitro-L-arginine and N-nitro-L-arginine methyl ester. The method of treatment with these drugs includes administration in various forms by various routes.

Abstract: This invention relates to treatment of betaglobin disorders, such as sickle-cell anemia and beta-thalassemia, by administering compositions of isobutyramide.

Abstract: Methods of treating Irritable Bowel Syndrome (IBS) using a series of isoxazole derivatives that have both 5-HT1A agonist and M1 muscarinic activities, and formulations adapted for the treatment of IBS comprising those derivatives.

Abstract: Methods and products for promoting hair growth, preventing or minimizing hair loss, enhancing or restoring hair color or remelanization and treating other hair and skin afflictions are disclosed. The methods includes topical application of the products to the skin or hair follicles being treated. The product includes as an essential component a treatment agent in an amount effective for treating the affliction and selected from the class of chemicals consisting of anol, anethole, analogs of the above, polymers of the above and mixtures thereof. Various combinations of these chemicals may be found in herb families including umbelliferae, magnoliaceae, labiatae and rutaceae. The invention preferably contemplates selecting the treatment agent from the class of herbs consisting of Foeniculum vulgares (fennel seed), Pimpinella anisum (anise), Carum carvi (caraway seeds) and mixtures of the above herbs with each other and/or with other herbs.

Abstract: Administration of ubidecarenone is effective for the therapy of sleep apnea. It is given at a dose of 1-3,000 mg per day in adults. It is especially effective to administer ubidecarenone to the patient before bed at a dose of 2-50 mg.

Abstract: A skin care composition in the form of a substantially oil-free aqueous gel comprising a water-soluble humectant, a hydrophilic gelling agent and a specific silicone component. The compositions provide improved skin feel and residue characteristics together with excellent moisturizing, emolliency, rub-in and absorption characteristics.

Abstract: Method of treating addiction to alcohol and symptoms related to withdrawal of said alcohol comprising the administration of certain 4-[bis(halophenyl)methylene]-1-piperidinyl derivatives.

Abstract: There is disclosed a pharmaceutical composition for inhibiting platelet aggregation comprising 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof and a 1,5-benzothiazepine derivative of the formula: ##STR1## wherein R.sup.1 is a lower alkyl group or a lower alkoxy group, R.sup.2 is a lower alkanoyl group, R.sup.3 and R.sup.4 are a lower alkyl group and R.sup.5 is hydrogen atom, a lower alkyl group or a halogen atom, or a pharmaceutically acceptable salt thereof.

Abstract: A therapeutic process for treating anemias in primates, including man, particularly those anemias of genetic origin including sickle-cell anemia, which comprises administering to an anemic primate an amount of a polyhydroxy benzoic, mandelic or phenylacetic acid derivative as specified at a dose level sufficient to increase fetal hemoglobin.

Abstract: Methods of inhibiting the proliferation of Plasmodium or Babesia parasites are provided by the present invention. Such methods may be useful for treating malaria and babesiosis in mammals such as humans.

Abstract: The present invention relates to an anxiolytic drug comprising as an active ingredient a 1-amino-5-halogenouracil represented by formula [I]: ##STR1## wherein X represents a halogen atom, or pharmaceutically acceptable salt thereof.